DIASORIN ETI-AB-AUK PLUS ASSAY

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P990042

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the diasorin eti-ab-auk plus assay. The device is indicated for: eti-ab-auk plus is an in vitro enzyme immunoassay (eia) intended for the qualitative detection of antibodies to hepatitis b surface antigen (anti-hbs) in human erum or plasma (edta, citrate or heparin). The eti-ab-auk plus is intended for manual use only. The detection of anti-hbs is indicative of laboratory diagnosis for seroconversion from hepatitis b virus (hbv) infection. Anti-hbs is also used to assess laboratory diagnosis of past exposure to hepatitis b in potential hepatitis b vaccine recipients and to determine the presence os an immune response in vaccine recipients. The anti-hbs assay's performance has not been established for the monitoring of hvb disease or therapy.

DeviceDIASORIN ETI-AB-AUK PLUS ASSAY
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantDIASORIN, INC.
Date Received1999-07-02
Decision Date2001-03-30
Notice Date2001-10-09
PMAP990042
SupplementS
Product CodeLOM
Docket Number01M-0453
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address DIASORIN, INC. 1951 Northwestern Ave. stillwater, MN 55082-0285
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P990042Original Filing
S028 2021-11-23 30-day Notice
S027 2020-07-16 30-day Notice
S026 2019-08-28 30-day Notice
S025 2019-06-18 30-day Notice
S024 2018-05-30 30-day Notice
S023 2018-03-30 30-day Notice
S022
S021 2018-02-14 30-day Notice
S020 2017-09-18 30-day Notice
S019 2017-04-25 30-day Notice
S018 2017-03-29 30-day Notice
S017 2016-05-10 30-day Notice
S016 2014-06-05 30-day Notice
S015 2013-12-27 30-day Notice
S014 2013-06-05 30-day Notice
S013 2012-11-09 Special (immediate Track)
S012
S011 2012-02-17 30-day Notice
S010 2011-10-18 30-day Notice
S009 2009-11-13 135 Review Track For 30-day Notice
S008 2008-12-22 Normal 180 Day Track
S007 2004-04-05 30-day Notice
S006 2003-04-07 Normal 180 Day Track No User Fee
S005 2002-10-30 30-day Notice
S004 2002-07-10 Normal 180 Day Track
S003 2002-04-04 Normal 180 Day Track
S002 2002-01-24 Normal 180 Day Track
S001 2001-09-07 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.